Hjem › Burkitts lymfom › Washington › Tacoma
Kliniske studier for Burkitts lymfom i Tacoma, WA
3 studier for Burkitts lymfom søker deltakere på steder i og rundt Tacoma (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
- Mary Bridge Children's Hospital and Health Center, Tacoma
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
- Mary Bridge Children's Hospital and Health Center, Tacoma
- Madigan Army Medical Center, Tacoma
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruttererFase 3
- Mary Bridge Children's Hospital and Health Center, Tacoma
Burkitts lymfom-studier i andre byer
- Houston, TX21 studier
- Milwaukee, WI16 studier
- Philadelphia, PA16 studier
- New York City, NY14 studier
- Chicago, IL14 studier
- Cincinnati, OH12 studier
- Atlanta, GA12 studier
- Seattle, WA11 studier
- Durham, NC10 studier
- Boston, MA10 studier
- Los Angeles, CA10 studier
- Aurora, CO10 studier
Andre studier i Tacoma
- Ikke-småcellet lungekreft20 studier
- Brystkreft18 studier
- Ulcerøs kolitt15 studier
- Multipelt myelom13 studier
- Prostatakreft11 studier
- Crohns sykdom11 studier
- Metastatisk kreft9 studier
- Kolorektal kreft9 studier
- Melanom7 studier
- Eggstokkreft7 studier
- Kreft (alle typer)6 studier
- Pankreaskreft6 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.